Christopher J Hoffmann

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa
    Christopher J Hoffmann
    Center for TB Research, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    J Int AIDS Soc 17:18871. 2014
  2. pmc Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa
    Christopher J Hoffmann
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Antivir Ther 18:915-20. 2013
  3. pmc High prevalence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant women in South Africa
    Christopher J Hoffmann
    Center for TB Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 8:e62211. 2013
  4. pmc Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model
    Christopher J Hoffmann
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Acquir Immune Defic Syndr 63:105-11. 2013
  5. pmc CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa
    Christopher J Hoffmann
    Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Acquir Immune Defic Syndr 63:34-41. 2013
  6. pmc Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa
    C J Hoffmann
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    Int J STD AIDS 23:e10-3. 2012
  7. pmc Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa
    Christopher J Hoffmann
    Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
    Clin Infect Dis 49:1928-35. 2009
  8. pmc Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa
    Christopher J Hoffmann
    Aurum Institute, Johannesburg, South Africa
    AIDS 24:1709-16. 2010
  9. pmc Hepatitis B and long-term HIV outcomes in coinfected HAART recipients
    Christopher J Hoffmann
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
    AIDS 23:1881-9. 2009
  10. pmc Changing predictors of mortality over time from cART start: implications for care
    Christopher J Hoffmann
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Acquir Immune Defic Syndr 58:269-76. 2011

Research Grants

  1. Hepatoxicity in an African HIV Treatment Cohort
    Christopher Hoffmann; Fiscal Year: 2006
  2. Hepatoxicity in an African HIV Treatment Cohort
    Christopher Hoffmann; Fiscal Year: 2008

Detail Information

Publications25

  1. pmc Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa
    Christopher J Hoffmann
    Center for TB Research, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
    J Int AIDS Soc 17:18871. 2014
    ..We describe maternal chronic hepatitis B (CHB) prevalence and infant infection during the first year of life within a cohort of women living with HIV...
  2. pmc Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa
    Christopher J Hoffmann
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Antivir Ther 18:915-20. 2013
    ..We sought to describe K65R development during TDF use in a cohort of patients infected with subtype C HIV...
  3. pmc High prevalence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant women in South Africa
    Christopher J Hoffmann
    Center for TB Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 8:e62211. 2013
    ..The poor performance of symptom screening to identify women with TB suggests that other approaches may be needed for intensified case-finding to be effective for this population...
  4. pmc Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model
    Christopher J Hoffmann
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Acquir Immune Defic Syndr 63:105-11. 2013
    ..To estimate the mortality impact of delay in antiretroviral therapy (ART) initiation from the time of entry into care...
  5. pmc CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa
    Christopher J Hoffmann
    Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Acquir Immune Defic Syndr 63:34-41. 2013
    ..We examined whether the CD4 count slope over 6 months could provide additional prognostic information...
  6. pmc Prevalence and associations with hepatitis B and hepatitis C infection among HIV-infected adults in South Africa
    C J Hoffmann
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    Int J STD AIDS 23:e10-3. 2012
    ..0% and specificity of 99.6%. In conclusion, we identified a moderate prevalence of both HBsAg and anti-HBc. Importantly, we found that subjects with HBsAg positivity had lower CD4 counts...
  7. pmc Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa
    Christopher J Hoffmann
    Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
    Clin Infect Dis 49:1928-35. 2009
    ..Episodes of viremia are common in African antiretroviral therapy (ART) programs. We sought to describe viremia, resuppression, and accumulation of resistance during first-line combination ART (cART) in South Africa...
  8. pmc Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa
    Christopher J Hoffmann
    Aurum Institute, Johannesburg, South Africa
    AIDS 24:1709-16. 2010
    ..To assess the effectiveness of cotrimoxazole preventive therapy (CPT) among individuals with CD4 cell count above 200 cells/microl and varying WHO clinical stages in reducing mortality during combination antiretroviral therapy (cART)...
  9. pmc Hepatitis B and long-term HIV outcomes in coinfected HAART recipients
    Christopher J Hoffmann
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
    AIDS 23:1881-9. 2009
    ..Chronic hepatitis B (CH-B) is common among HIV-infected individuals and increases liver-related mortality in the absence of HAART. The impact of CH-B on long-term HAART outcomes has not been fully characterized...
  10. pmc Changing predictors of mortality over time from cART start: implications for care
    Christopher J Hoffmann
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Acquir Immune Defic Syndr 58:269-76. 2011
    ..To determine predictors of mortality and changes in those predictors over time on combination antiretroviral therapy (cART) in South Africa...
  11. pmc Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events
    Christopher J Hoffmann
    Aurum Institute for Health Research, Johannesburg, South Africa
    AIDS 22:67-74. 2008
    ..To describe the safety and tolerability of zidovudine, lamivudine, and efavirenz in a low-income setting...
  12. ncbi request reprint Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B
    Christopher J Hoffmann
    Aurum Institute for Health Research, Johannesburg, South Africa
    AIDS 21:1301-8. 2007
    ..Hepatotoxicity is a significant complication of antiretroviral therapy (ART). We assessed the incidence of and risk factors for hepatotoxicity among HIV-infected individuals on ART in South Africa...
  13. ncbi request reprint Clinical implications of HIV and hepatitis B co-infection in Asia and Africa
    Christopher J Hoffmann
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Lancet Infect Dis 7:402-9. 2007
    ..This Review discusses the epidemiology, natural history, pathogenesis, and management of HIV/HBV co-infection from these areas. Topics for future research relevant to HIV/HBV co-infection in Africa and Asia are also highlighted...
  14. pmc Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program
    Christopher J Hoffmann
    Aurum Institute for Health Research and 2Toga Laboratories, Johannesburg, South Africa
    Clin Infect Dis 47:1479-85. 2008
    ..We evaluated the impact of chronic hepatitis B on HIV virologic response, changes in CD4 cell count, hepatotoxicity, and mortality among Africans receiving highly active antiretroviral therapy (HAART)...
  15. pmc Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme
    Salome Charalambous
    The Aurum Institute, Johannesburg, South Africa
    AIDS 24:S5-13. 2010
    ..To describe the association between isoniazid preventive therapy (IPT) and mortality among individuals starting antiretroviral therapy (ART) in a workplace programme in South Africa where tuberculosis (TB) incidence is very high...
  16. pmc HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa
    Christopher J Hoffmann
    Aurum Institute for Health Research, Johannesburg, South Africa
    AIDS 23:1784-6. 2009
    ..6). In regression modeling, including baseline HIV RNA and nonnucleoside reverse transcriptase inhibitor agent, stavudine dose remained unassociated with suppression...
  17. pmc Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study
    Kavindhran Velen
    The Aurum Institute, Johannesburg, South Africa
    PLoS ONE 8:e64459. 2013
    ....
  18. pmc Epidemiology of tuberculosis and HIV: recent advances in understanding and responses
    Neil A Martinson
    Center for TB Research, Johns Hopkins University School of Medicine, Baltimore Maryland 21231, USA
    Proc Am Thorac Soc 8:288-93. 2011
    ..Combating TB in high HIV-prevalence settings requires rapid and massive implementation of the 3I's with initiation of antiretrovirals and more effective efforts to prevent new HIV infections...
  19. pmc A novel HIV treatment model using private practitioners in South Africa
    Craig Innes
    The Aurum Institute, Johannesburg, South Africa
    Sex Transm Infect 88:136-40. 2012
    ..The extent of the HIV epidemic in South Africa may render the public sector capacity inadequate to manage all patients requiring antiretroviral treatment (ART). Private practitioners are an underutilised resource...
  20. pmc Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation
    Christopher J Hoffmann
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Transplantation 86:784-90. 2008
    ..Solid organ transplant recipients commonly are infected with hepatitis viruses, are immunosuppressed, and have other potential hepatocellular carcinoma (HCC) risk factors...
  21. pmc Cotrimoxazole Prophylaxis and Tuberculosis Risk among People Living with HIV
    Christopher J Hoffmann
    Johns Hopkins University School of Medicine and Center for TB Research, Baltimore, Maryland, United States of America
    PLoS ONE 9:e83750. 2014
    ..We sought to compare TB incidence and TB diagnostic yield by cotrimoxazole use among participants in a well characterized cohort of HIV-infected adults living in a high TB prevalence region...
  22. pmc Four Models of HIV Counseling and Testing: Utilization and Test Results in South Africa
    Tonderai Mabuto
    The Aurum Institute, Johannesburg, South Africa
    PLoS ONE 9:e102267. 2014
    ..We describe HCT utilization and HIV diagnosis using four models of HCT delivery: clinic-based, urban mobile, rural mobile, and stand-alone...
  23. ncbi request reprint Initial regimens for the treatment-naive patient: current understanding and practice
    Christopher J Hoffmann
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS Read 18:326-30, 336-8. 2008
  24. ncbi request reprint Thyroid function abnormalities in HIV-infected patients
    Christopher J Hoffmann
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
    Clin Infect Dis 45:488-94. 2007
    ....
  25. pmc Neurocysticercosis in Oregon, 1995-2000
    John M Townes
    Division of Infectious Diseases, Oregon Health and Science University, Mail Code L 457, 3181 SW Sam Jackson Park Road, Portland, OR 97201 3098, USA
    Emerg Infect Dis 10:508-10. 2004
    ..At least five cases occurred in persons who had not traveled or lived outside the United States. Enhanced surveillance for neurocysticercosis is warranted...

Research Grants2

  1. Hepatoxicity in an African HIV Treatment Cohort
    Christopher Hoffmann; Fiscal Year: 2006
    ..It will be conducted within a large and on-going ARV cohort established as a collaborative project between a South African industrial conglomerate and Johns Hopkins University. [unreadable] [unreadable]..
  2. Hepatoxicity in an African HIV Treatment Cohort
    Christopher Hoffmann; Fiscal Year: 2008
    ..It will be conducted within a large and on-going ARV cohort established as a collaborative project between a South African industrial conglomerate and Johns Hopkins University. [unreadable] [unreadable]..